

Nazia Selzner

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6910042/publications.pdf>

Version: 2024-02-01

161
papers

6,648
citations

81839

39
h-index

74108

75
g-index

165
all docs

165
docs citations

165
times ranked

9427
citing authors

#	ARTICLE	IF	CITATIONS
1	Liver Retransplantation Using Living Donor Grafts: A Western Experience. <i>Liver Transplantation</i> , 2022, 28, 887-890.	1.3	5
2	Superior Long-Term Outcomes of Adult Living Donor Liver Transplantation: A Cumulative Single-Center Cohort Study With 20 Years of Follow-Up. <i>Liver Transplantation</i> , 2022, 28, 834-842.	1.3	13
3	Risk factors and outcomes associated with recurrent autoimmune hepatitis following liver transplantation. <i>Journal of Hepatology</i> , 2022, 77, 84-97.	1.8	21
4	We thank Bekki et al and Bhagat et al for their comments on our article "Results of Early Transplantation for Alcohol-Related Cirrhosis: Integrated Addiction Treatment with Low Rate of Relapse". Bekki et al pointed out a trend toward inferior graft sur.... <i>Gastroenterology</i> , 2022, .	0.6	0
5	Anonymity: What does it mean and why is it important to anonymous living liver donors?. <i>Liver Transplantation</i> , 2022, 28, 1299-1305.	1.3	0
6	Recipient and Donor Outcomes After Living-Donor Liver Transplant for Unresectable Colorectal Liver Metastases. <i>JAMA Surgery</i> , 2022, 157, 524.	2.2	48
7	Feasibility of a Home-Based Exercise Program for Managing Posttransplant Metabolic Syndrome in Lung and Liver Transplant Recipients: Protocol for a Pilot Randomized Controlled Trial. <i>JMIR Research Protocols</i> , 2022, 11, e35700.	0.5	1
8	Ethnicity, disease severity, and survival in Canadian patients with primary biliary cholangitis. <i>Hepatology</i> , 2022, 76, 303-316.	3.6	6
9	Association between social determinants of health and rates of liver transplantation in individuals with cirrhosis. <i>Hepatology</i> , 2022, 76, 1079-1089.	3.6	13
10	Assessment of long-term outcomes post living liver donation highlights the importance of scientific integrity when presenting transplant registry data. <i>American Journal of Transplantation</i> , 2022, 22, 1519-1522.	2.6	1
11	Evaluation of a gene expression biomarker to identify operationally tolerant liver transplant recipients: the LITMUS trial. <i>Clinical and Experimental Immunology</i> , 2022, 207, 123-139.	1.1	4
12	Anonymous living liver donor perspectives on the role of family in their donation experience. <i>Clinical Transplantation</i> , 2022, 36, e14556.	0.8	1
13	The role of acute in-patient rehabilitation on short-term outcomes after liver transplantation: A systematic review of the literature and expert panel recommendations. <i>Clinical Transplantation</i> , 2022, 36, e14706.	0.8	8
14	Are MELD and MELDNa Still Reliable Tools to Predict Mortality on the Liver Transplant Waiting List?. <i>Transplantation</i> , 2022, 106, 2122-2136.	0.5	4
15	Single-Center North American Experience of Liver Transplantation in Autoimmune Hepatitis: Infrequent Indication but Good Outcomes for Patients. <i>Journal of the Canadian Association of Gastroenterology</i> , 2021, 4, 137-144.	0.1	6
16	Living donor liver paired exchange: A North American first. <i>American Journal of Transplantation</i> , 2021, 21, 400-404.	2.6	19
17	Evaluation of Recombinant Herpes Zoster Vaccine for Primary Immunization of Varicella-seronegative Transplant Recipients. <i>Transplantation</i> , 2021, 105, 2316-2323.	0.5	24
18	Cumulative Deficits Frailty Index Predicts Outcomes for Solid Organ Transplant Candidates. <i>Transplantation Direct</i> , 2021, 7, e677.	0.8	18

#	ARTICLE	IF	CITATIONS
19	The hippo pathway: A master regulator of liver metabolism, regeneration, and disease. <i>FASEB Journal</i> , 2021, 35, e21570.	0.2	30
20	Enhanced Recovery for Liver Transplantation. <i>Transplantation</i> , 2021, Publish Ahead of Print, .	0.5	2
21	Defatting strategies in the current era of liver steatosis. <i>JHEP Reports</i> , 2021, 3, 100265.	2.6	11
22	Normothermic Ex Situ Liver Perfusion Enhances Mitochondrial Function of DCD Grafts as Evidenced by High-throughput Metabolomics. <i>Transplantation</i> , 2021, 105, 1530-1538.	0.5	4
23	Early Allograft Dysfunction After Liver Transplantation With Donation After Circulatory Death and Brain Death Grafts: Does the Donor Type Matter?. <i>Transplantation Direct</i> , 2021, 7, e727.	0.8	5
24	Pregnancy Outcomes After Living Liver Donation: A Multi-Institutional Study. <i>Liver Transplantation</i> , 2021, 27, 1262-1272.	1.3	6
25	Trends in indications and outcomes of liver transplantation in Canada: A multicenter retrospective study. <i>Transplant International</i> , 2021, 34, 1444-1454.	0.8	11
26	Results of Early Transplantation for Alcohol-Related Cirrhosis: Integrated Addiction Treatment With Low Rate of Relapse. <i>Gastroenterology</i> , 2021, 161, 1896-1906.e2.	0.6	37
27	Sex Disparity in Liver Transplant and Access to Living Donation. <i>JAMA Surgery</i> , 2021, 156, 1010.	2.2	12
28	Canadian Society of Transplantation White Paper: Ethical and Legal Considerations for Alcohol and Cannabis Use in Solid Organ Listing and Allocation. <i>Transplantation</i> , 2021, 105, 1957-1964.	0.5	6
29	The Impact of Primary Liver Disease and Social Determinants in a Mixed Donor Liver Transplant Program: A Single-Center Analysis. <i>Liver Transplantation</i> , 2021, 27, 1733-1746.	1.3	7
30	PSC recurrence post liver transplantation: retransplantation justified or not?. <i>Transplant International</i> , 2021, 34, 1754-1755.	0.8	0
31	Randomized Trial of a Third Dose of mRNA-1273 Vaccine in Transplant Recipients. <i>New England Journal of Medicine</i> , 2021, 385, 1244-1246.	13.9	456
32	Outcomes of Highly Selected Live Donors With a Future Liver Remnant Less Than or Equal to 30%: A Matched Cohort Study. <i>Transplantation</i> , 2021, 105, 2397-2403.	0.5	6
33	Outcomes of living donors are worse than those of matched healthy controls: Is the matching group appropriate?. <i>Journal of Hepatology</i> , 2021, , .	1.8	2
34	Cell-Mediated Immune Responses After Influenza Vaccination of Solid Organ Transplant Recipients: Secondary Outcomes Analyses of a Randomized Controlled Trial. <i>Journal of Infectious Diseases</i> , 2020, 221, 53-62.	1.9	10
35	Clinical predictors of progression and clearance of low-level CMV DNAemia in solid organ transplant recipients. <i>Transplant Infectious Disease</i> , 2020, 22, e13207.	0.7	9
36	Cytomegalovirus: The "Troll of Transplantation" Is Now the "Troll of Tolerance". <i>Transplantation</i> , 2020, 104, 238-239.	0.5	2

#	ARTICLE	IF	CITATIONS
37	The Impact of Direct-acting Antivirals on Overall Mortality and Tumoral Recurrence in Patients With Hepatocellular Carcinoma Listed for Liver Transplantation: An International Multicenter Study. <i>Transplantation</i> , 2020, 104, 2087-2096.	0.5	12
38	Women benefit more from having a potential living liver donor than men. <i>Journal of Hepatology</i> , 2020, 73, S257-S258.	1.8	0
39	Normothermic Ex Vivo Liver Perfusion Prevents Intrahepatic Platelet Sequestration After Liver Transplantation. <i>Transplantation</i> , 2020, 104, 1177-1186.	0.5	6
40	Renal Dysfunction After Liver Transplantation: Effect of Donor Type. <i>Liver Transplantation</i> , 2020, 26, 799-810.	1.3	13
41	Liver Transplantation for Colorectal and Neuroendocrine Liver Metastases and Hepatoblastoma. Working Group Report From the ILTS Transplant Oncology Consensus Conference. <i>Transplantation</i> , 2020, 104, 1131-1135.	0.5	30
42	Donor outcomes in anonymous live liver donation. <i>Journal of Hepatology</i> , 2019, 71, 951-959.	1.8	43
43	THU-342-Development of a model to predict survival in recipients of liver transplant for non-alcoholic steatohepatitis. <i>Journal of Hepatology</i> , 2019, 70, e310-e311.	1.8	0
44	Prognosis, Prevention and Research Prospects of Progression to Severe Hepatitis B (Liver Failure). , 2019, , 457-497.		0
45	Liver Transplantation for Acute Liver Failure Due to Dengue Fever. <i>Hepatology</i> , 2019, 70, 1863-1865.	3.6	12
46	Predictor parameters of liver viability during porcine normothermic ex situ liver perfusion in a model of liver transplantation with marginal grafts. <i>American Journal of Transplantation</i> , 2019, 19, 2991-3005.	2.6	25
47	Attitudes of Liver Transplant Candidates Toward Organs From Increased-Risk Donors. <i>Liver Transplantation</i> , 2019, 25, 881-888.	1.3	14
48	Obesity: Weighty Challenges for the Liver Transplant Community. <i>Liver Transplantation</i> , 2019, 25, 531-532.	1.3	1
49	Impact of Different Clinical Perfusates During Normothermic Ex Situ Liver Perfusion on Pig Liver Transplant Outcomes in a DCD Model. <i>Transplantation Direct</i> , 2019, 5, e437.	0.8	8
50	The Impact of Preexisting and Post-transplant Diabetes Mellitus on Outcomes Following Liver Transplantation. <i>Transplantation</i> , 2019, 103, 2523-2530.	0.5	37
51	Predictors of De Novo Nonalcoholic Fatty Liver Disease After Liver Transplantation and Associated Fibrosis. <i>Liver Transplantation</i> , 2019, 25, 56-67.	1.3	51
52	Steatosis in Liver Transplantation: Current Limitations and Future Strategies. <i>Transplantation</i> , 2019, 103, 78-90.	0.5	71
53	Outcomes of radiofrequency ablation as first-line therapy for hepatocellular carcinoma less than 3 cm in potentially transplantable patients. <i>Journal of Hepatology</i> , 2019, 70, 866-873.	1.8	96
54	Live donor liver transplantation for patients with hepatocellular carcinoma offers increased survival vs. deceased donation. <i>Journal of Hepatology</i> , 2019, 70, 666-673.	1.8	66

#	ARTICLE	IF	CITATIONS
55	Expanding the donor pool: Donation after circulatory death and living liver donation do not compromise the results of liver transplantation. <i>Liver Transplantation</i> , 2018, 24, 779-789.	1.3	65
56	Should organs from hepatitis C-positive donors be used in hepatitis C-negative recipients for liver transplantation?. <i>Liver Transplantation</i> , 2018, 24, 831-840.	1.3	34
57	Inhibition of the Fibrinogen-Like Protein 2:Fc β 3 γ 1/2 β 3 γ 1 immunosuppressive pathway enhances antiviral T α cell and B α cell responses leading to clearance of lymphocytic choriomeningitis virus clone 13. <i>Immunology</i> , 2018, 154, 476-489.	2.0	11
58	Machine Preservation of the Liver: What Is the Future Holding?. <i>Current Transplantation Reports</i> , 2018, 5, 82-92.	0.9	2
59	Evaluation of a Novel Global Immunity Assay to Predict Infection in Organ Transplant Recipients. <i>Clinical Infectious Diseases</i> , 2018, 66, 1392-1397.	2.9	46
60	Surgical Complications after Right Hepatectomy for Live Liver Donation: Largest Single-Center Western World Experience. <i>Seminars in Liver Disease</i> , 2018, 38, 134-144.	1.8	38
61	Combined lung-liver-pancreas transplantation in a recipient with cystic fibrosis. <i>Journal of Cystic Fibrosis</i> , 2018, 17, e1-e4.	0.3	16
62	Comparison of BQ123, Epoprostenol, and Verapamil as Vasodilators During Normothermic Ex Vivo Liver Machine Perfusion. <i>Transplantation</i> , 2018, 102, 601-608.	0.5	33
63	Can negligible hepatic steatosis determined by magnetic resonance imaging α “proton density fat fraction obviate the need for liver biopsy in potential liver donors?. <i>Liver Transplantation</i> , 2018, 24, 470-477.	1.3	31
64	Alpha-fetoprotein dynamics in the waiting list as a biomarker of hepatocellular carcinoma recurrence and mortality after liver transplant. <i>Hpb</i> , 2018, 20, S234.	0.1	0
65	In vivo and In vitro PPAR- γ Activation Decreases M1-Macrophage Polarization and Improves Liver Ischemia Reperfusion Injury. <i>Transplantation</i> , 2018, 102, S708.	0.5	0
66	Living Donor Liver Transplantation Using Selected Grafts With 2 Bile Ducts Compared With 1 Bile Duct Does Not Impact Patient Outcome. <i>Liver Transplantation</i> , 2018, 24, 1512-1522.	1.3	23
67	Single cell RNA sequencing of human liver reveals distinct intrahepatic macrophage populations. <i>Nature Communications</i> , 2018, 9, 4383.	5.8	958
68	Splenectomy as Flow Modulation Strategy and Risk Factors of De Novo Portal Vein Thrombosis in Adult α “Adult Living Donor Liver Transplantation. <i>Liver Transplantation</i> , 2018, 24, 1209-1220.	1.3	14
69	Live donor liver transplantation with older donors: Increased long α “term graft loss due to α “HCV α “ recurrence. <i>Clinical Transplantation</i> , 2018, 32, e13304.	0.8	3
70	Acute on chronic liver failure-comparison of patients identified by the European association for the study of the liver and the North American consortium for study of end-stage liver diseases. <i>Journal of Hepatology</i> , 2018, 68, S241.	1.8	0
71	PPAR- γ activation is associated with reduced liver ischemia-reperfusion injury and altered tissue-resident macrophages polarization in a mouse model. <i>PLoS ONE</i> , 2018, 13, e0195212.	1.1	37
72	Fat and liver transplantation: clinical implications. <i>Transplant International</i> , 2018, 31, 828-837.	0.8	19

#	ARTICLE	IF	CITATIONS
73	Living donation to the extreme: Saving a life not once, but twice. Liver Transplantation, 2017, 23, 288-289.	1.3	3
74	Liver Transplantation is a Preferable Alternative to Palliative Therapy for Selected Patients with Advanced Hepatocellular Carcinoma. Annals of Surgical Oncology, 2017, 24, 1843-1851.	0.7	14
75	Early Intervention With Live Donor Liver Transplantation Reduces Resource Utilization in NASH: The Toronto Experience. Transplantation Direct, 2017, 3, e158.	0.8	12
76	Characteristics of liver transplant candidates delisted following recompensation and predictors of such delisting in alcohol-related liver disease: a case-control study. Transplant International, 2017, 30, 1140-1149.	0.8	21
77	Bridging to liver transplantation in HCC patients. Langenbeck's Archives of Surgery, 2017, 402, 863-871.	0.8	38
78	Elevated Preoperative Serum Bilirubin Improves Reperfusion Injury and Survival Postliver Transplantation. Transplantation Direct, 2017, 3, e187.	0.8	5
79	Inducing Hepatitis C Virus Resistance After Pig Liver Transplantation—A Proof of Concept of Liver Graft Modification Using Warm Ex Vivo Perfusion. American Journal of Transplantation, 2017, 17, 970-978.	2.6	66
80	Donor BMI >30 Is Not a Contraindication for Live Liver Donation. American Journal of Transplantation, 2017, 17, 756-762.	2.6	34
81	Avoiding ICU Admission by Using a Fast-Track Protocol Is Safe in Selected Adult-to-Adult Live Donor Liver Transplant Recipients. Transplantation Direct, 2017, 3, e213.	0.8	10
82	Overexpression of fibrinogen-like protein 2 protects against T cell-induced colitis. World Journal of Gastroenterology, 2017, 23, 2673.	1.4	12
83	Fostering liver living donor liver transplantation. Current Opinion in Organ Transplantation, 2016, 21, 224-230.	0.8	23
84	Live Donor Liver Transplantation With Older (>50 Years) Versus Younger (<50 Years) Donors. Annals of Surgery, 2016, 263, 979-985.	2.1	35
85	Treatment with Optifast reduces hepatic steatosis and increases candidacy rates for living donor liver transplantation. Liver Transplantation, 2016, 22, 1295-1300.	1.3	29
86	Recurrent primary sclerosing cholangitis in the Adult-to-Adult Living Donor Liver Transplantation Cohort Study: Comparison of risk factors between living and deceased donor recipients. Liver Transplantation, 2016, 22, 1214-1222.	1.3	51
87	Normothermic ex vivo liver perfusion using steen solution as perfusate for human liver transplantation: First North American results. Liver Transplantation, 2016, 22, 1501-1508.	1.3	167
88	First-Degree Living-Related Donor Liver Transplantation in Autoimmune Liver Diseases. American Journal of Transplantation, 2016, 16, 3512-3521.	2.6	23
89	The extended Toronto criteria for liver transplantation in patients with hepatocellular carcinoma: A prospective validation study. Hepatology, 2016, 64, 2077-2088.	3.6	256
90	Protease inhibitors partially overcome the interferon nonresponse phenotype in patients with chronic hepatitis C. Journal of Viral Hepatitis, 2016, 23, 340-347.	1.0	1

#	ARTICLE	IF	CITATIONS
91	Lipopolysaccharide and Tumor Necrosis Factor Alpha Inhibit Interferon Signaling in Hepatocytes by Increasing Ubiquitin-Like Protease 18 (USP18) Expression. <i>Journal of Virology</i> , 2016, 90, 5549-5560.	1.5	30
92	Anti-inflammatory signaling during ex vivo liver perfusion improves the preservation of pig liver grafts before transplantation. <i>Liver Transplantation</i> , 2016, 22, 1573-1583.	1.3	60
93	Subnormothermic ex vivo liver perfusion is a safe alternative to cold static storage for preserving standard criteria grafts. <i>Liver Transplantation</i> , 2016, 22, 111-119.	1.3	33
94	Should We Exclude Live Donor Liver Transplantation for Liver Transplant Recipients Requiring Mechanical Ventilation and Intensive Care Unit Care?. <i>Transplantation Direct</i> , 2015, 1, e30.	0.8	5
95	Technique of Porcine Liver Procurement and Orthotopic Transplantation using an Active Porto-Caval Shunt. <i>Journal of Visualized Experiments</i> , 2015, , e52055.	0.2	7
96	Reply. <i>Liver Transplantation</i> , 2015, 21, 1333-1334.	1.3	0
97	High preoperative bilirubin values protect against reperfusion injury after live donor liver transplantation. <i>Transplant International</i> , 2015, 28, 1317-1325.	0.8	12
98	Recipient factors associated with having a potential living donor for liver transplantation. <i>Liver Transplantation</i> , 2015, 21, 897-903.	1.3	12
99	Liver transplantation in patients with end-stage liver disease requiring intensive care unit admission and intubation. <i>Liver Transplantation</i> , 2015, 21, 761-767.	1.3	36
100	Early Clinical Results Using Normothermic Machine Liver Preservation. <i>Current Transplantation Reports</i> , 2015, 2, 74-80.	0.9	2
101	Live Donor Liver Transplantation: A Valid Alternative for Critically Ill Patients Suffering From Acute Liver Failure. <i>American Journal of Transplantation</i> , 2015, 15, 1591-1597.	2.6	31
102	Infiltrative (sinusoidal) and hepatitic patterns of injury in acute cellular rejection in liver allograft with clinical implications. <i>Modern Pathology</i> , 2015, 28, 1275-1281.	2.9	14
103	Role of Regulatory T Cells (Treg) and the Treg Effector Molecule Fibrinogen-like Protein 2 in Alloimmunity and Autoimmunity. <i>Rambam Maimonides Medical Journal</i> , 2015, 6, e0024.	0.4	15
104	One Year of Hepatitis B Immunoglobulin Plus Tenofovir Therapy is Safe and Effective in Preventing Recurrent Hepatitis B Infection Post-Liver Transplantation. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2014, 28, 41-44.	0.8	29
105	Living vs. Deceased Donor Liver Transplantation Provides Comparable Recovery of Renal Function in Patients With Hepatorenal Syndrome: A Matched Case-Control Study. <i>American Journal of Transplantation</i> , 2014, 14, 2788-2795.	2.6	39
106	Protein Interferon-Stimulated Gene 15 Conjugation Delays but Does Not Overcome Coronavirus Proliferation in a Model of Fulminant Hepatitis. <i>Journal of Virology</i> , 2014, 88, 6195-6204.	1.5	18
107	Enteral Energy and Macronutrients in End-stage Liver Disease. <i>Journal of Parenteral and Enteral Nutrition</i> , 2014, 38, 673-681.	1.3	23
108	Technique of Subnormothermic Ex Vivo Liver Perfusion for the Storage, Assessment, and Repair of Marginal Liver Grafts. <i>Journal of Visualized Experiments</i> , 2014, , e51419.	0.2	19

#	ARTICLE	IF	CITATIONS
109	Subnormothermic ex vivo liver perfusion reduces endothelial cell and bile duct injury after donation after cardiac death pig liver transplantation. <i>Liver Transplantation</i> , 2014, 20, 1296-1305.	1.3	56
110	Normothermic Acellular Ex Vivo Liver Perfusion Reduces Liver and Bile Duct Injury of Pig Livers Retrieved After Cardiac Death. <i>American Journal of Transplantation</i> , 2013, 13, 1441-1449.	2.6	105
111	The Impact of Obesity as Determined by Modified Body Mass Index on Long-Term Outcome After Liver Transplantation: Canadian Single-Center Experience. <i>Transplantation Proceedings</i> , 2013, 45, 2288-2294.	0.3	30
112	Angiotensin Blockade Does Not Affect Fibrosis Progression in Recurrent Hepatitis C After Liver Transplantation. <i>Transplantation Proceedings</i> , 2013, 45, 2331-2336.	0.3	8
113	Normothermic Acellular Ex Vivo Liver Perfusion (NEVLP) Reduces Liver and Bile Duct in DCD Liver Grafts. <i>American Journal of Transplantation</i> , 2013, 13, 3290.	2.6	10
114	Measurements of serial plasma levels of albumin mRNA for management of patients post transplant: Does it add value?. <i>Clinical Biochemistry</i> , 2013, 46, 1311-1312.	0.8	1
115	Virological response for recurrent hepatitis C improves long-term survival in liver transplant recipients. <i>Transplant International</i> , 2013, 26, 42-49.	0.8	14
116	Normothermic Machine Perfusion of Discarded Liver Grafts—What Is Viable?. <i>American Journal of Transplantation</i> , 2013, 13, 2503.	2.6	5
117	Serum Aspartate Aminotransferase Level and Previous Histopathological Findings Enable Reduction of Protocol Liver Biopsies after Liver Transplantation for Hepatitis C. <i>Canadian Journal of Gastroenterology & Hepatology</i> , 2013, 27, 131-136.	1.8	2
118	Targeted Deletion of FGL2 Leads to Increased Early Viral Replication and Enhanced Adaptive Immunity in a Murine Model of Acute Viral Hepatitis Caused by LCMV WE. <i>PLoS ONE</i> , 2013, 8, e72309.	1.1	19
119	FGL2/Fibroleukin mediates hepatic reperfusion injury by induction of sinusoidal endothelial cell and hepatocyte apoptosis in mice. <i>Journal of Hepatology</i> , 2012, 56, 153-159.	1.8	41
120	Hepatic Cell—Type Specific Gene Expression Better Predicts HCV Treatment Outcome Than IL28B Genotype. <i>Gastroenterology</i> , 2012, 142, 1122-1131.e1.	0.6	61
121	Role of regulatory T cells in the promotion of transplant tolerance. <i>Liver Transplantation</i> , 2012, 18, 761-770.	1.3	36
122	Routine Induction Therapy in Living Donor Liver Transplantation Prevents Rejection but May Promote Recurrence of Hepatitis C. <i>Transplantation Proceedings</i> , 2012, 44, 1351-1356.	0.3	10
123	Preconditioning, postconditioning, and remote conditioning in solid organ transplantation: basic mechanisms and translational applications. <i>Transplantation Reviews</i> , 2012, 26, 115-124.	1.2	68
124	The prothrombinase activity of FGL2 contributes to the pathogenesis of experimental arthritis. <i>Scandinavian Journal of Rheumatology</i> , 2011, 40, 269-278.	0.6	34
125	Immune-mediated complications of the graft in interferon-treated hepatitis C positive liver transplant recipients. <i>Journal of Hepatology</i> , 2011, 55, 207-217.	1.8	97
126	Live Donor Liver Transplantation in High MELD Score Recipients. <i>Annals of Surgery</i> , 2010, 251, 153-157.	2.1	101

#	ARTICLE	IF	CITATIONS
127	Adult Living Liver Donors have Excellent Long-Term Medical Outcomes: The University of Toronto Liver Transplant Experience. <i>American Journal of Transplantation</i> , 2010, 10, 364-371.	2.6	93
128	The immunosuppressive pipeline: Meeting unmet needs in liver transplantation. <i>Liver Transplantation</i> , 2010, 16, 1359-1372.	1.3	22
129	The novel immunoregulatory molecule FGL2: A potential biomarker for severity of chronic hepatitis C virus infection. <i>Journal of Hepatology</i> , 2010, 53, 608-615.	1.8	54
130	The Role of FGL2 in the Pathogenesis and Treatment of Hepatitis C Virus Infection. <i>Rambam Maimonides Medical Journal</i> , 2010, 1, e0004.	0.4	15
131	The novel CD4+CD25+ regulatory T cell effector molecule fibrinogen-like protein 2 contributes to the outcome of murine fulminant viral hepatitis. <i>Hepatology</i> , 2009, 49, 387-397.	3.6	78
132	Recipient age affects long-term outcome and hepatitis C recurrence in old donor livers following transplantation. <i>Liver Transplantation</i> , 2009, 15, 1288-1295.	1.3	53
133	Exaggerated up-regulation of tumor necrosis factor α -dependent apoptosis in the older mouse liver following reperfusion injury: Targeting liver protective strategies to patient age. <i>Liver Transplantation</i> , 2009, 15, 1594-1604.	1.3	22
134	A graft to body weight ratio less than 0.8 does not exclude adult-to-adult right-lobe living donor liver transplantation. <i>Liver Transplantation</i> , 2009, 15, 1776-1782.	1.3	96
135	Antiviral Treatment of Recurrent Hepatitis C After Liver Transplantation: Predictors of Response and Long-Term Outcome. <i>Transplantation</i> , 2009, 88, 1214-1221.	0.5	110
136	The difference in the fibrosis progression of recurrent hepatitis C after live donor liver transplantation versus deceased donor liver transplantation is attributable to the difference in donor age. <i>Liver Transplantation</i> , 2008, 14, 1778-1786.	1.3	65
137	Hepatic gene expression and prediction of therapy response in chronic hepatitis C patients. <i>Journal of Hepatology</i> , 2008, 48, 708-713.	1.8	20
138	Can genetic variations predict HCV treatment outcomes?. <i>Journal of Hepatology</i> , 2008, 49, 494-497.	1.8	14
139	Increased ischemic injury in old mouse liver: An ATP-dependent mechanism. <i>Liver Transplantation</i> , 2007, 13, 382-390.	1.3	116
140	¹³ C-methacetin breath test as a quantitative liver function test in patients with chronic hepatitis C infection: continuous automatic molecular correlation spectroscopy compared to isotopic ratio mass spectrometry. <i>Alimentary Pharmacology and Therapeutics</i> , 2007, 26, 305-311.	1.9	36
141	Mouse livers with macrosteatosis are more susceptible to normothermic ischemic injury than those with microsteatosis. <i>Journal of Hepatology</i> , 2006, 44, 694-701.	1.8	127
142	Downstaging colorectal liver metastases by concomitant unilateral portal vein ligation and selective intra-arterial chemotherapy. <i>British Journal of Surgery</i> , 2006, 93, 587-592.	0.1	51
143	Principles of Liver Preservation. , 2005, , 561-573.		0
144	Water induces autocrine stimulation of tumor cell killing through ATP release and P2 receptor binding. <i>Cell Death and Differentiation</i> , 2004, 11, S172-S180.	5.0	38

#	ARTICLE	IF	CITATIONS
145	Liver regeneration after adult living donor and deceased donor split-liver transplants. Liver Transplantation, 2004, 10, 1078-1078.	1.3	3
146	Protective strategies against ischemic injury of the liver. Gastroenterology, 2003, 125, 917-936.	0.6	482
147	ICAM-1 triggers liver regeneration through leukocyte recruitment and Kupffer cell-dependent release of TNF- α /IL-6 in mice. Gastroenterology, 2003, 124, 692-700.	0.6	186
148	Hepatic artery chemotherapy and colorectal liver metastases. Lancet, The, 2003, 361, 1742.	6.3	0
149	Hepatic artery chemotherapy and colorectal liver metastases. Lancet, The, 2003, 361, 1742-1743.	6.3	2
150	Ischemic preconditioning protects the steatotic mouse liver against reperfusion injury: an ATP dependent mechanism. Journal of Hepatology, 2003, 39, 55-61.	1.8	112
151	Living donor liver transplantation in patients with portal vein thrombosis: a survey and review of technical issues. Transplantation, 2002, 74, 696-701.	0.5	41
152	Transgenic mice overexpressing human Bcl-2 are resistant to hepatic ischemia and reperfusion. Journal of Hepatology, 2002, 36, 218-225.	1.8	64
153	Hepatic ischemic preconditioning is most effective in patients with a small resection volume and long ischemic intervals: a prospective randomized study in 100 patients. Journal of Hepatology, 2002, 36, 31-32.	1.8	4
154	Ischemic preconditioning mediates protection through reversible burst of oxidative stress in mice. Journal of Hepatology, 2002, 36, 74.	1.8	0
155	Downstaging of hepatocellular carcinoma and liver metastases from colorectal cancer by selective intra-arterial chemotherapy. Surgery, 2002, 131, 433-442.	1.0	91
156	Cryosurgery After Chemoembolization for Hepatocellular Carcinoma in Patients With Cirrhosis. Journal of Gastrointestinal Surgery, 2002, 6, 95-101.	0.9	20
157	Cold ischemia decreases liver regeneration after partial liver transplantation in the rat: A TNF- α /IL-6-dependent mechanism. Hepatology, 2002, 36, 812-818.	3.6	99
158	CONVERSION FROM CYCLOSPORINE TO FK506 IN ADULT LIVER TRANSPLANT RECIPIENTS: A COMBINED NORTH AMERICAN AND EUROPEAN EXPERIENCE. Transplantation, 2001, 72, 1061-1065.	0.5	27
159	Liver Disease Due to Alcohol. , 0, , 226-234.		0
160	Ischaemia-Reperfusion Injury to the Liver. , 0, , 348-355.		0
161	Management of Portal Hypertension and Biliary Problems Prior to Transplantation. , 0, , 43-65.		0